Complement Therapeutics Limited

Company description

Complement Therapeutics researches how to improve the lives of patients with complement dysregulation that causes chronic illness.

Spin-out company to develop therapeutics and analytics for patient stratification and monitoring which target the complement system, with a primary focus on age-related macular degeneration.

Project impact

The company is only finishing its financing round in Q1 2021, but the lead product CTx001 (a gene therapy for common retinal disease) is aimed to be in phase I clinical trials by Q4 2022.

Company founded mid-2020. Initial SEED funding round closed with EURO 6M investment at Feb2022 Series A funding closed April 2023 - EURO 72M 2 Further patents submitted Company Laboratories opened in Stevenage Q3 2023 Innovate UK EDGE funding secured MHRA Innovation Passport Granted Non-interventional multinational clinical study started - >250 patients recruited as Jan 2025. Winners of European Lifestar awards Series A raise of the year and Finalist in Scrip Awards (Biotech of the Year) - both 2023

Our lead product, CTx001, is in pre-clinical development for the localised treatment of Geographic Atrophy ('dry' age-related macular degeneration). In addition, we are developing therapeutics that are aimed at systemic modulation of the complement system. We anticipate that these assets will meet the needs of a wide range of patients with complement-mediated disease. Identified and corrected: flaws in other previous Complement-related approaches to treating Geographic Atrophy The flaws we have identified have prevented these other therapies from delivering their intended effects. In developing our own approaches, we have carefully analysed all aspects of the Complement System, investigated where therapies to date have fallen down and explored how we should avoid the flaws we have identified. Given the strategic importance of Chialexin (now known as CTx002) and Coalexin (CTx001), we never actually published any of our PoC data. We have, however, filled seven patents around the technology either directly or as a result of their use. All of the assets and IP are assigned from the UoM to Complement Therapeutics (see https://complementtx.com). The outcome of the funding is quite unusual as it was the first step (of many) that led to the founding of a UoM spin-out company Complement Therapeutics (see https://complementtx.com/), which recently raised €5million in seed funding. While the product at the centre of the CiC funding itself was not a raging success, the knowledge and data gained med to a second generation product that led to the formation of the company. However, the 'ghost' of this project lives on and the IP generated is incorporated into the company and is currently being revived as one of the company's alternative assets.

Company founded mid-2020. Initial SEED funding round closed with EURO 5M investment at Feb2022